Liposomal azelaic acid 20% cream vs hydroquinone 4% cream as adjuvant to oral tranexamic acid in melasma: a comparative study

References

• McKesey J, Tovar-Garza A, Pandya AG. Melasma treatment: an evidence-based review. Am J Clin Dermatol. 2020;21(2):173–225.
   PubMed Web of Science ®Google Scholar
• Lee AY. Recent progress in melasma pathogenesis. Pigment Cell Melanoma Res. 2015;28(6):648–660.
   PubMed Web of Science ®Google Scholar
• Sociedade Brasileira de Dermatologia, Miot HA, Penna GO, et al. Profile of dermatological consultations in Brazil (2018). An Bras Dermatol. 2018;93(6):916–928.
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Pandya AG. Melasma: clinical diagnosis and management options. Australas J Dermatol. 2015;56(3):151–163.
   PubMed Web of Science ®Google Scholar
• Suggs AK, Hamill SS, Friedman PM. Melasma: update on management. Semin Cutan Med Surg. 2018;37(4):217–225.
   PubMed Web of Science ®Google Scholar
• Sarkar R, Gokhale N, Godse K, et al. Medical management of melasma: a review with consensus recommendations by indian pigmentary expert group. Indian J Dermatol. 2017;62(6):558–577.
   PubMed Web of Science ®Google Scholar
• Ogbechie-Godec OA, Elbuluk N. Melasma: an up-to-date comprehensive review. Dermatol Ther . 2017;7(3):305–318.
   PubMed Web of Science ®Google Scholar
• Jutley GS, Rajaratnam R, Halpern J, et al. Systematic review of randomized controlled trials on interventions for melasma: an abridged Cochrane review. J Am Acad Dermatol. 2014;70(2):369–373.
   PubMed Web of Science ®Google Scholar
• Grimes PE, Ijaz S, Nashawati R, et al. New oral and topical approaches for the treatment of melasma. Int J Womens Dermatol. 2019;5(1):30–36.
   PubMedGoogle Scholar
• Abou-Taleb DA, Ibrahim AK, Youssef EM, et al. Reliability, validity, and sensitivity to change overtime of the modified melasma area and severity index score. Dermatol Surg. 2017;43(2):210–217.
   PubMed Web of Science ®Google Scholar
• Wootton CI, Bell S, Philavanh A, et al. Assessing skin disease and associated health-related quality of life in a rural Lao community. BMC Dermatol. 2018;18(1):11.
   PubMedGoogle Scholar
• Pollo CF, Miot LDB, Meneguin S, et al. Factors associated with quality of life in facial melasma: a cross-sectional study. Int J Cosmet Sci. 2018;40(3):313–316.
   Web of Science ®Google Scholar
• Schulte BC, Wu W, Rosen T. Azelaic acid: evidence-based update on mechanism of action and clinical application. J Drugs Dermatol. 2015;14(9):964–968.
   PubMed Web of Science ®Google Scholar
• Del Rosso JQ. Azelaic acid topical formulations: differentiation of 15% gel and 15% foam. J Clin Aesthet Dermatol. 2017;10(3):37–40.
   PubMedGoogle Scholar
• Tomić I, Juretić M, Jug M, et al. Preparation of in situ hydrogels loaded with azelaic acid nanocrystals and their dermal application performance study. Int J Pharm. 2019;563:249–258.
   PubMed Web of Science ®Google Scholar
• Choi MJ, Maibach HI. Liposomes and niosomes as topical drug delivery systems. Skin Pharmacol Physiol. 2005;18(5):209–219.
   PubMed Web of Science ®Google Scholar
• Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011;65(4):699–714.
   PubMedGoogle Scholar
• Shankar K, Godse K, Aurangabadkar S, et al. Evidence-based treatment for melasma: expert opinion and a review. Dermatol Ther. 2014;4(2):165–186.
   Google Scholar
• Gong Z, Lai W, Zhao G, et al. Efficacy and safety of fluocinolone acetonide, hydroquinone, and tretinoin cream in chinese patients with melasma: a randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Clin Drug Investig. 2015;35(6):385–395.
   PubMed Web of Science ®Google Scholar
• Tyler KH, Zirwas MJ. Pregnancy and dermatologic therapy. J Am Acad Dermatol. 2013;68(4):663–671.
   PubMed Web of Science ®Google Scholar
• Sardana K, Ghunawat S. Rationale of using hypopigmenting drugs and their clinical application in melasma. Expert Rev Clin Pharmacol. 2015;8(1):123–134.
   PubMed Web of Science ®Google Scholar
• Briganti S, Flori E, Mastrofrancesco A, et al. Azelaic acid reduced senescence-like phenotype in photo-irradiated human dermal fibroblasts: possible implication of PPARγ. Exp Dermatol. 2013;22(1):41–47.
   PubMed Web of Science ®Google Scholar
• Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31(4):461–465.
   PubMed Web of Science ®Google Scholar
• Kwon SH, Hwang YJ, Lee SK, et al. Heterogeneous pathology of melasma and its clinical implications. IJMS. 2016;17(6):824.
   Google Scholar
• Dayal S, Sahu P, Dua R. Combination of glycolic acid peel and topical 20% azelaic acid cream in melasma patients: efficacy and improvement in quality of life. J Cosmet Dermatol. 2017;16(1):35–42.
   PubMed Web of Science ®Google Scholar
• Lajevardi V, Ghayoumi A, Abedini R, et al. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up. J Cosmet Dermatol. 2017;16(2):235–242.
   PubMed Web of Science ®Google Scholar
• Shihab N, Prihartono J, Tovar-Garza A, et al. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma. Australas J Dermatol. 2020;61(3):237–242.
   PubMed Web of Science ®Google Scholar
• Sahu PJ, Singh AL, Kulkarni S, et al. Study of oral tranexamic acid, topical tranexamic acid, and modified Kligman's regimen in treatment of melasma. J Cosmet Dermatol. 2020;19(6):1456–1462.
   PubMed Web of Science ®Google Scholar
• Minni K, Poojary S. Efficacy and safety of oral tranexamic acid as an adjuvant in Indian patients with melasma: a prospective, interventional, single-centre, triple-blind, randomized, placebo-control, parallel group study. J Eur Acad Dermatol Venereol. 2020;34(11):2636–2644.
   PubMed Web of Science ®Google Scholar
• Perper M, Eber AE, Fayne R, et al. Tranexamic acid in the treatment of melasma: a review of the literature. Am J Clin Dermatol. 2017;18(3):373–381.
   PubMed Web of Science ®Google Scholar
• Masub N, Nguyen JK, Austin E, et al. The vascular component of melasma: a systematic review of laboratory, diagnostic, and therapeutic evidence. Dermatol Surg. 2020;46(12):1642–1650.
   PubMed Web of Science ®Google Scholar
• Zhou LL, Baibergenova A. Melasma: systematic review of the systemic treatments. Int J Dermatol. 2017;56(9):902–908.
   PubMed Web of Science ®Google Scholar
• Bala HR, Lee S, Wong C, et al. Oral tranexamic acid for the treatment of melasma: a review. Dermatol Surg. 2018;44(6):814–825.
   PubMed Web of Science ®Google Scholar
• Zhu CY, Li Y, Sun QN, et al. Analysis of the effect of different doses of oral tranexamic acid on melasma: a multicentre prospective study. Eur J Dermatol. 2019;29(1):55–58.
   PubMed Web of Science ®Google Scholar
• Carita AC, Eloy JO, Chorilli M, et al. Recent advances and perspectives in liposomes for cutaneous drug delivery. Curr Med Chem. 2018;25(5):606–635.
   PubMedGoogle Scholar
• Banihashemi M, Zabolinejad N, Jaafari MR, et al. Comparison of therapeutic effects of liposomal tranexamic acid and conventional hydroquinone on melasma. J Cosmet Dermatol. 2015;14(3):174–177.
   PubMed Web of Science ®Google Scholar
• Xing X, Chen L, Xu Z, et al. The efficacy and safety of topical tranexamic acid (liposomal or lotion with microneedling) versus conventional hydroquinone in the treatment of melasma. J Cosmet Dermatol. 2020;19(12):3238–3244.
   PubMed Web of Science ®Google Scholar
• Huh SY, Shin JW, Na JI, et al. Efficacy and safety of liposome-encapsulated 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial. J Dermatol. 2010;37(4):311–315.
   PubMed Web of Science ®Google Scholar
• Kwon SH, Yang JH, Shin JW, et al. Efficacy of liposome-encapsulated 4-n-butylresorcinol and resveratrol cream in the treatment of melasma. J Cosmet Dermatol. 2020;19(4):891–895.
   PubMed Web of Science ®Google Scholar
• Taghavi F, Banihashemi M, Zabolinejad N, et al. Comparison of therapeutic effects of conventional and liposomal form of 4% topical hydroquinone in patients with melasma. J Cosmet Dermatol. 2019;18(3):870–873.
   PubMed Web of Science ®Google Scholar